Skip to main content
Clinical Trials/NCT04012073
NCT04012073
Terminated
Phase 3

Individualized Positive End-expiRatory Pressure Guided by End-Expiratory Lung Volume in Moderate-to-severe Acute resPiratory Distress Syndrome.The IPERPEEP Study

Fondazione Policlinico Universitario Agostino Gemelli IRCCS10 sites in 1 country18 target enrollmentNovember 1, 2022

Overview

Phase
Phase 3
Intervention
Invasive Mechanical ventilation
Conditions
Respiratory Distress Syndrome, Adult
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
18
Locations
10
Primary Endpoint
Composite clinical outcome that incorporates ICU mortality, 60-day ventilation-free days (VFD60) and the Area Under the Curve of the InterLeukin-6 serum concentration (IL6AUC) during the first 72 hours of observation
Status
Terminated
Last Updated
7 months ago

Overview

Brief Summary

During the acute respiratory distress syndrome (ARDS), patients' response to positive end-expiratory pressure (PEEP) is variable according to different degrees of lung recruitability. The search for a tool to individualize PEEP on the basis of patients' individual response is warranted.

Measurement of end-expiratory lung volume (EELV) by the nitrogen washin-washout technique, bedside available from recent ICU ventilators, has been shown to reliably estimate PEEP-induced alveolar recruitment and may therefore help titrate PEEP on patient's individual requirements.

The authors designed an open-label, multicenter, randomized trial to test whether an individualized PEEP setting protocol driven by EELV may improve a composite clinical outcome in patients with moderate-to-severe ARDS.

Detailed Description

ARDS patients with a PaO2/FiO2 ratio equal or below 150 mmHg (during mechanical ventilation with PEEP 5 cmH2O) will be enrolled within 24 hours from endo-tracheal intubation. To standardize lung volumes at study initiation, all patients will undergo mechanical ventilation with tidal volume set at 6 ml/kg of predicted body weight and PEEP set to obtain a plateau pressure within 28 and 30 cmH2O for thirty minutes (Express PEEP). Afterwards, a 5-step decremental PEEP trial will be conducted (Express PEEP to PEEP 5 cmH2O), and EELV will be measured at each step. PEEP-induced alveolar recruitment will be calculated for each PEEP range as the difference between PEEP-induced change EELV and the predicted increase in lung volume due to PEEP (PEEP-induced overdistension, equal to the product of respiratory system compliance and PEEP change). Patients will be then randomized to receive mechanical ventilation with PEEP set according to the optimal recruitment observed in the PEEP trial (IPERPEEP arm) trial or according to the Express strategy (Control arm, PEEP set to achieve a plateau pressure of 28-30 cmH2O). In both groups, tidal volume size, the use of prone positioning and neuromuscular blocking agents will be standardized. Primary endpoint of the study is a composite clinical outcome incorporating in-ICU mortality, 60-day ventilator free days and the area under the curve of serum Interleukin 6 over the course of the initial 72 hours. Primary and secondary endpoints will also be analyzed in subgroups, as defined below: * ∆EELV5-16/FRC ≥ 73% \[18\] during the PEEP trial * ∆EELV5-16/FRC \< 73%\[23\] during the PEEP trial * Recruitment-to-inflation ratio (RI) ≥ 1 and \<1 across the range between the lowest and highest PEEP tested during the PEEP trial * P/F ratio\<100 mmHg at study inclusion * IL-6\>400 pg/ml at study inclusion

Registry
clinicaltrials.gov
Start Date
November 1, 2022
End Date
June 30, 2025
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Pneumothorax;
  • Acute brain injury;
  • Clinical signs of history of decompensated heart failure (New York Heart Association class 3-4 before the acute phase of the disease or documented ejection fraction\<35% or pulmonary capillary wedge pressure\>18 mmHg) or acute coronary syndrome;
  • Intubation as a result of an acute exacerbation of chronic pulmonary disease: chronic obstructive pulmonary disease, asthma, cystic fibrosis, etc;
  • Clinically evident intrinsic PEEP (≥2 cmH2O) during screening visit (End-expiratory pause to achieve Flow=0);
  • BMI\<15 or body weight\<35 Kg;
  • Any chronic disease requiring long-term oxygen therapy or mechanical ventilation at home;
  • Neuromuscular disease of any kind;
  • Severe chronic liver disease (Child-Pugh C or worse);
  • Bone marrow transplantation or chemotherapy-induced neutropenia;

Arms & Interventions

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Invasive Mechanical ventilation

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Neuromuscular Blocking Agents

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Prone positioning

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Resume of spontaneous breathing

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Rescue treatments

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Weaning from PEEP

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Weaning from mechanical ventilation

IPERPEEP

End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial. PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O. In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting. * RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP. * RI\<0.5 will lead to the setting of the lower PEEP value. * In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics.

Intervention: Extubation

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Extubation

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Invasive Mechanical ventilation

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Neuromuscular Blocking Agents

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Prone positioning

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Resume of spontaneous breathing

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Rescue treatments

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Weaning from PEEP

EXPRESS

PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O

Intervention: Weaning from mechanical ventilation

Outcomes

Primary Outcomes

Composite clinical outcome that incorporates ICU mortality, 60-day ventilation-free days (VFD60) and the Area Under the Curve of the InterLeukin-6 serum concentration (IL6AUC) during the first 72 hours of observation

Time Frame: 60 days

Composite clinical outcome that incorporates ICU mortality, 60-day ventilation-free days (VFD60) and the Area Under the Curve of the InterLeukin-6 serum blood cytokine concentration (IL6AUC) during the first 72 hours of observation. Every participant in the treatment group will be compared with every participant in the control group and assigned a score resulting from each comparison. Mortality takes precedence over VFD60, which takes precedence over IL6AUC. Two VFD60's will be considered different for the purpose of scoring only if their difference is larger than 5 days. Similarly, two IL6AUC's measurements will be considered different only if their difference exceeds 10% of the smaller of the two. These individual-comparison scores are added up to obtain the cumulative score primary endpoint for each participant. The sum of scores for patients in the treatment group is compared to the sum of scores of subjects in the control group and compared according by use of Mann-Whitney test

Secondary Outcomes

  • AUC IL-6(72 hours)
  • Total Lung stress-End-inspiratory transpulmonary pressure derived from elastance ratio(72 hours)
  • In-ICU mortality(90 days)
  • 90-day mortality(90 days)
  • 28-day Ventilator free days(28 days)
  • Arterial pressure(72 hours)
  • In-Hospital mortality(90 days)
  • 60-day Ventilator free days(28 days)
  • Time to successful weaning(90 days)
  • Set PEEP variability(72 hours)
  • Time spent on assisted ventilation after the enrolment(28 days)
  • AUC IL-8(72 hours)
  • End-expiratory transpulmonary pressure(72 hours)
  • Respiratory system compliance(72 hours)
  • Oxygenation(72 hours)
  • Oxygenation stretch index(72 hours)
  • Carbon dioxide(72 hours)
  • Heart rate(72 hours)
  • Organ failure(28 days)
  • Need for rescue recruitment maneuvers(72 hours)
  • Plateau pressure(72 hours)
  • Respiratory system driving pressure(72 hours)
  • AUC TNF(72 hours)
  • Set PEEP(72 hours)
  • Simplified organ failure assessment(28 days)
  • Nedd for rescue extra-corporeal membrane oxygenation(90 days)
  • Nedd for tracheostomy(90 days)
  • Static stress(72 hours)
  • Dynamic stress-Transpulmonary driving pressure(72 hours)
  • Respiratory system compliance normalized to predicted body weight(72 hours)
  • Lung compliance(72 hours)
  • Dynamic strain(30 minutes)
  • Static strain(30 minutes)
  • Catecholamine requirements per day(72 hours)

Study Sites (10)

Loading locations...

Similar Trials